Who are the women blazing trails in biopharma R&D? Nominate them for Endpoints' special report
Gender imbalance in the average corporate boardroom is endemic, and the biopharma world is no exception. Data suggest women are woefully underrepresented in leadership roles, holding just 20% of these seats at biopharma firms.
Last year, when we asked the Endpoints 100 — the group of biotech execs we rely on to measure industry-wide sentiments in a semi-annual survey — how the industry was performing on gender diversity, there was a consensus that it could do better. One way to do this, is to encourage and celebrate the women who have climbed the ladder, despite the odds.
We are therefore putting together a special report to recognize the growing number of enterprising women who have made it to the top by supercharging drug R&D. These roles could include CEOs, CMOs, CSOs and R&D directors and the like who have left an impression at your workplace, or at any other firm within the industry.
For those that have already sent across your suggestions, thank you! We are now extending the final call to the rest: we are accepting nominations until the end of this week, i.e. March 29. Email her name, current role and the reason for nomination to us:
You can also use the following nomination form:
We’ll see you again when the report gets out in June. Meanwhile, feel free to share any thoughts you have on the topic.
— Natalie Grover and Amber Tong